期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 30, 期 8, 页码 581-593出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2020.1776263
关键词
Ghrelin; ghrelinO-acyltransferase; GHS-R1a receptor; membrane-boundO-acyltransferase; protein acylation; diabetes; obesity; metabolic syndrome; addiction; alcoholism
资金
- National Institutes of Health [GM134102]
- American Diabetes Association [1-16-JDF-042]
- Syracuse University
Introduction The peptide hormone ghrelin regulates physiological processes associated with energy homeostasis such as appetite, insulin signaling, glucose metabolism, and adiposity. Ghrelin has also been implicated in a growing number of neurological pathways involved in stress response and addiction behavior. For ghrelin to bind the growth hormone secretagogue receptor 1a (GHS-R1a) and activate signaling, the hormone must first be octanoylated on a specific serine side chain. This key transformation is performed by the enzyme ghrelinO-acyltransferase (GOAT), and therefore GOAT inhibitors may be useful in treating disorders related to ghrelin signaling such as diabetes, obesity, and related metabolic syndromes. Areas covered This report covers ghrelin and GOAT as potential therapeutic targets and summarizes work on GOAT inhibitors through the end of 2019, highlighting recent successes with both peptidomimetics and small molecule GOAT inhibitors as potent modulators of GOAT-catalyzed ghrelin octanoylation. Expert opinion A growing body of biochemical and structural knowledge regarding the ghrelin/GOAT system now enables multiple avenues for identifying and optimizing GOAT inhibitors. We are at the beginning of a new era with increased opportunities for leveraging ghrelin and GOAT in the understanding and treatment of multiple health conditions including diabetes, obesity, and addiction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据